Deflazacort oral suspension is indicated for the treatment of Duchenne Muscular Dystrophy (DMD) in patients aged five years and older. Shares of Zydus Lifesciences Ltd ended at ₹994.55, up by ₹5.80, or 0.59%, on the BSE.
Deflazacort oral suspension is indicated for the treatment of Duchenne Muscular Dystrophy (DMD) in patients aged five years and older. Shares of Zydus Lifesciences Ltd ended at ₹994.55, up by ₹5.80, or 0.59%, on the BSE.